Targeted therapeutics that change the way diseases are being treated
KaloBios’ patented proprietary Humaneered® technology platform is designed to address problems of therapeutic antibodies (e.g., specificity, affinity, immunogenicity etc.), as well as equally important downstream processing issues (e.g., solubility, expression, aggregation, etc.). The process is fast and produces antibodies close to human germ-line in sequence while retaining the specificity and improving the affinity of the reference antibody. Humaneered® antibodies have now been tested clinically and to date no anti-drug antibodies have been detected even after dosing healthy human volunteers.
- Engineered human
- Low/No immunogenicity
- Equal or higher affinity than starting antibody
- Solves antibody problems:
- Expression level (in both mammalian and microbial systems)
- Binding kinetics (select for Ka vs. Kd)
This novel system allows a true alternative to classic antibody engineering technologies, bringing a cost advantage to our pipeline as well as the opportunity to provide service to others.
KaloBios' Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products.Learn More